Oppenheimer set a $13.00 price objective on Alpine Immune Sciences (NASDAQ:ALPN) in a report released on Tuesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock. Oppenheimer also issued estimates for Alpine Immune Sciences’ Q1 2019 earnings at ($0.58) EPS, Q2 2019 earnings at ($0.57) EPS, Q3 2019 earnings at ($0.59) EPS, Q4 2019 earnings at ($0.61) EPS, FY2019 earnings at ($2.35) EPS, FY2020 earnings at ($2.28) EPS, FY2021 earnings at ($2.39) EPS, FY2022 earnings at ($2.45) EPS and FY2023 earnings at ($2.29) EPS.
A number of other research analysts have also issued reports on the company. ValuEngine upgraded Alpine Immune Sciences from a sell rating to a hold rating in a report on Tuesday, March 5th. reiterated a buy rating and issued a $13.00 target price on shares of Alpine Immune Sciences in a report on Tuesday, February 12th. Finally, Zacks Investment Research upgraded Alpine Immune Sciences from a hold rating to a buy rating and set a $7.00 target price for the company in a report on Thursday, January 24th. Two research analysts have rated the stock with a hold rating and six have assigned a buy rating to the stock. The company has an average rating of Buy and a consensus price target of $12.00.
Shares of NASDAQ ALPN opened at $6.82 on Tuesday. Alpine Immune Sciences has a twelve month low of $3.66 and a twelve month high of $10.57. The company has a quick ratio of 9.20, a current ratio of 6.59 and a debt-to-equity ratio of 0.05. The firm has a market capitalization of $97.12 million, a PE ratio of -2.59 and a beta of 2.13.
In other Alpine Immune Sciences news, insider Mitchell Gold purchased 190,875 shares of the firm’s stock in a transaction on Friday, January 18th. The stock was bought at an average cost of $5.37 per share, with a total value of $1,024,998.75. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Also, major shareholder Tiger Management L.L.C. sold 25,000 shares of Alpine Immune Sciences stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $5.85, for a total value of $146,250.00. The disclosure for this sale can be found here. Company insiders own 69.00% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in ALPN. Hikari Power Ltd purchased a new stake in Alpine Immune Sciences during the 4th quarter worth about $453,000. Victory Capital Management Inc. lifted its holdings in Alpine Immune Sciences by 109.0% during the 4th quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after buying an additional 70,980 shares during the last quarter. Vanguard Group Inc lifted its holdings in Alpine Immune Sciences by 5.2% during the 3rd quarter. Vanguard Group Inc now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares during the last quarter. Finally, Vanguard Group Inc. lifted its holdings in Alpine Immune Sciences by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after buying an additional 11,200 shares during the last quarter. 53.83% of the stock is owned by institutional investors.
Alpine Immune Sciences Company Profile
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Read More: Dividend
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.